|
Anemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
The JAK2-selective inhibitor fedratinib has recently been resurrected, and there has been a resurgence of interest in the failed JAK1/2 inhibitor momelotinib, which possibly improves anemia.
|
30675650 |
2019 |
|
Anemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Combined Janus kinase 1 (JAK1) and JAK2 inhibition therapy effectively reduces splenomegaly and symptom burden related to myelofibrosis but is associated with dose-dependent anemia and thrombocytopenia.
|
27789678 |
2017 |
|
Anemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Anemia is a significant problem and adverse prognostic factor in over a third of MF patients and is often worsened by JAK2 inhibitors.
|
27785927 |
2017 |
|
Anemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Early side effects seen with other less selective JAK inhibitors were not observed (e.g., there was no worsening of anemia [JAK-2 inhibition related], no effects on liver transaminases, and no increase in low-density lipoprotein or total cholesterol).
|
28622463 |
2017 |
|
Anemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Furthermore WT1 is a good marker of response to JAK2 inhibitors especially for patients without blasts and for patients who develop anemia or thrombocytopenia not for progression but as therapy related toxicity.
|
27167495 |
2016 |
|
Anemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In primary myelofibrosis patients, the degree of anemia was less severe in those who were CALR exon 9 mutation-positive than in those who were JAK2 V617F-positive (p = 0.048).
|
25323779 |
2015 |
|
Anemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
However, they often accentuate the anemia and do not reduce the JAK2 allele burden, therefore lacking the potential to modify the natural history of MF.
|
23514013 |
2013 |
|
Anemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
It is possible that an optimal balance between JAK-1-inhibitory and JAK-2-inhibitory activities may broaden the therapeutic activity (i.e. anemia improvement), as has been preliminarily seen (CYT387).
|
21245760 |
2011 |
|
Anemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Median mutation levels in pretreatment ET samples were significantly higher for MPL-mutated cases (60%) than for JAK2-mutated cases (24%; P=0.01), as was presentation with anemia.
|
20113830 |
2010 |
|
Anemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
New medical therapies for MF revolve around three main themes: immunomodulation (to assist anemia), hypomethylation strategies, and (the most robust pipeline) the use of targeted JAK2 inhibitors.
|
20425392 |
2010 |
|
Anemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In patients with CMD, the multivariate generalized linear regression model showed that the JAK2 (V617F) mutational burden (P = 0.01), serum lactate dehydrogenase level (P = 0.003), and anaemia (P < 0.001) independently correlated with MVD.
|
18028479 |
2008 |
|
Anemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
When compared with MPL wild-type patients, irrespective of JAK2(V617F) status, those with MPL(W515L/K), were more frequently female, were older (61 years vs. 57 years; P = 0.02), presented with more severe anaemia (haemoglobin, 101 g/l vs. 121 g/l; P = 0.002) and were more likely to require regular transfusional support (P = 0.012).
|
17408465 |
2007 |
|
Anemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Apoptotic resistance in MMM correlated with anemia (P=0.01) and the JAK2-V617F (P=0.01).
|
16871275 |
2006 |
|
Anemia
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|